As the saying goes, good things come to those who wait, and following a year of decline, patience might finally be paying off for investors of beaten-up Amneal Pharmaceuticals (AMRX).AMRX stock skyrocketed nearly 50% in Thursday’s trading session, following today’s announcement of Amneal receiving an FDA approval for EluRyng, the first generic version of NuvaRing.NuvaRing is a birth contraceptive which is applied in the same manner as a tampon. Once inserted, the small flexible ring releases a continuous low dose of hormones. With the release of EluRyng, Amneal is hoping to get a cut of NuvaRing’s market. Nuvaring US sales …read more
Source:: Yahoo Finance
